Document Detail

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
MedLine Citation:
PMID:  20553285     Owner:  NLM     Status:  MEDLINE    
AIMS: In a previous echocardiographic prevalence study we reported a significant increase in the frequency of heart valve regurgitation in patients with Parkinson's disease taking the ergot-derived dopamine agonists pergolide and cabergoline versus controls. We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time.
METHODS: Prospective follow-up of 101 patients treated with ergot-derived dopamine agonists included in the prevalence study: 53 given pergolide and 48 cabergoline (64% male; 66.4 ± 8.7 years of age, 11.5 ± 5.9 years of disease, 21.8 ± 5.9 months of follow-up); 55 stopped treatment while 46 continued. The main outcomes measures, were: echocardiographic quantification of regurgitant valve disease, abnormal leaflet, or cusp thickening and measurement of mitral valve tenting area.
RESULTS: Valve abnormalities regressed in about one third of patients with significant multivalvular and in about half of the patients with monovalvular regurgitation who withdrew; no progression was observed in remaining patients. Patients continuing ergot-derived dopamine agonists showed progression of cardiac valvulopathy: seven new cases with three to four regurgitation grade of any valve occurred during follow-up; this regarded also patients who had been on pergolide for many years.
CONCLUSION: Owing to the persistence of risk of heart valve damage over time and the lack of its mid-term reversibility in many patients, we believe that pergolide and cabergoline should be prescribed only when therapeutic alternatives with a better risk/benefit ratio are unavailable and the patient has access to echocardiography.
Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Related Documents :
8281475 - Pseudoaneurysm after bentall repair: magnetic resonance imaging assessment.
19346135 - Results of the double switch operation for congenitally corrected transposition of the ...
18850485 - Moderate mitral regurgitation in patients undergoing cabg--the momic trial.
19941695 - New findings concerning cardiovascular manifestations emerging from long-term follow-up...
20569725 - A multicenter, open-label study of vernakalant for the conversion of atrial fibrillatio...
19729905 - Association between markers of inflammation, fibrosis and hypervolemia in peritoneal di...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-11
Journal Detail:
Title:  Cardiovascular therapeutics     Volume:  29     ISSN:  1755-5922     ISO Abbreviation:  Cardiovasc Ther     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-28     Completed Date:  2012-03-25     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101319630     Medline TA:  Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  404-10     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Cardiac Rehabilitation Unit, Istituti Clinici diPerfezionamento, Via Bignami 1, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiparkinson Agents / adverse effects*
Dopamine Agonists / adverse effects*
Ergolines / adverse effects*
Follow-Up Studies
Heart Valve Diseases / chemically induced*,  epidemiology,  ultrasonography
Italy / epidemiology
Middle Aged
Parkinson Disease / drug therapy*,  epidemiology
Patient Selection
Pergolide / adverse effects*
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Reg. No./Substance:
0/Antiparkinson Agents; 0/Dopamine Agonists; 0/Ergolines; 66104-22-1/Pergolide; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Oxidative stress impairs endothelial function in nondipper hypertensive patients.
Next Document:  Prehypertension: the rationale for early drug therapy.